In der Downing Street in London residieren die englischen Premierminister.
Mittwoch, 21.12.2016 17:45 von | Aufrufe: 190

Johnson & Johnson Confirms Exclusive Negotiations with Actelion

In der Downing Street in London residieren die englischen Premierminister. pixabay.com

PR Newswire

NEW BRUNSWICK, N.J., Dec. 21, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today confirmed it has entered into exclusive negotiations with Actelion Ltd. (SIX: ATLN) regarding a potential transaction.

There can be no assurance any transaction will result from these discussions. Johnson & Johnson does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This communication contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the possibility that a potential transaction involving Actelion will not be entered into or completed; if a transaction is entered into, the terms and conditions of any such transaction; and whether the potential benefits of any transaction would be realized. In addition, if and when any transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson Family of Companies to successfully integrate the products and employees of Actelion, as well as the ability to ensure continued performance or market growth of its products. A further list and description of the risks, uncertainties and other factors related to the Johnson & Johnson Family of Companies can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and Johnson & Johnson's subsequent filings. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

This communication does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares in Actelion, or Actelion's ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for. There are no assurances that a transaction will be reached or on what terms.


ARIVA.DE Börsen-Geflüster

Werbung

Weiter abwärts?

Kurzfristig positionieren in Johnson & Johnson Corp.
VM1SQU
Ask: 1,84
Hebel: 20,92
mit starkem Hebel
Zum Produkt
VU4F7G
Ask: 3,16
Hebel: 6,61
mit moderatem Hebel
Zum Produkt
Smartbroker
Vontobel
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: VM1SQU,VU4F7G,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.

Kurse

-  
0,00%
Actelion ADR Chart
Johnson & Johnson Corp. Chart

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-confirms-exclusive-negotiations-with-actelion-300382591.html

SOURCE Johnson & Johnson

Werbung

Mehr Nachrichten zur Johnson & Johnson Corp. Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News